Severe COVID‐19 infection in a child receiving immunotherapy for cancer
Valeria R. Smith,Sarah B. Whittle,Ryan D. Coleman,Flor M. Munoz,Marietta M. De Guzman,Jennifer H. Foster,Shoba A. Navai
DOI: https://doi.org/10.1002/pbc.28710
2020-09-15
Abstract:To the Editor:An asymptomatic 23‐month‐old female with high‐risk neuroblastoma in remission was admitted for her third cycle of consolidation therapy with dinutuximab, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and isotretinoin.1 Surveillance testing for SARS‐CoV‐2 by real‐time polymerase chain reaction (rtPCR) 48 h prior to admission and contact screening were negative. On hospital day 4, she developed fever (103.5°F), tachypnea (respiratory rate 60), and hypoxemia (SpO2 93% on room air) attributed to immunotherapy‐related capillary leak syndrome.1 Dinutuximab and GM‐CSF were discontinued, while diuretics, antipyretics, antibiotics, and oxygen were initiated. Worsening fever, respiratory failure, and shock necessitated transfer to the intensive care unit for mechanical ventilation and vasoactive support. Repeat SARS‐CoV‐2 rtPCR was positive. Echocardiogram demonstrated severe pulmonary hypertension (tricuspid regurgitation jet 4.6 m/s), right atrial and ventricular dilation, and right ventricular dysfunction. Inhaled nitric oxide and iloprost were initiated for pulmonary hypertension, with epinephrine, vasopressin, and milrinone continuous infusions for hemodynamic support. Evaluation for coinfections was negative. Laboratory analyses revealed disseminated intravascular coagulation (prothrombin time 23.6 s, INR 2.1, partial thromboplastin time > 49.4 s, fibrinogen 159 mg/dL, D‐dimer 2.18 ug/mL), transaminitis (aspartate transaminase 508 U/L, alanine aminotransferase 166 U/L), inflammation (lactate dehydrogenase 2489 U/L, C‐reactive protein 7.3 mg/dL, ferritin 19 900 ng/mL), and cardiac dysfunction (brain natriuretic peptide 2589.4 pg/mL, troponin I 0.144 ng/mL).
oncology,pediatrics,hematology